Bristol Myers Squibb

News

Bristol-Myers Squibb has claimed its second FDA approval in just a few days for its Opdivo/Yervoy combination, this time in liver cancer.

News

The FDA has approved Bristol Myers Squibb's Opdivo and Yervoy as first-line therapy for patients with a particular form of colorectal cancer.

News

Bristol Myers Squibb has moved to take full control of the CAR-T therapy it partners with 2seventy bio, agreeing to buy the biotech for around $286m.

News

J&J wants to turn the screw in the psoriasis market with a new head-to-head trial pitting oral IL-23 drug icotrokinra against Stelara.

News

The FDA has started a priority review of Bristol Myers Squibb's Opdivo and Yervoy as first-line therapy for MSI-H/dMMR colorectal cancer.

News

Around 600 people with various types of B-cell lymphoma will be eligible for treatment with BMS' CAR-T therapy Breyanzi under new NICE guidance.